Edwards Lifesciences Corporation EW
NYSE
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 6.67B | 6.51B | 6.30B | 6.07B | 5.88B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 6.67B | 6.51B | 6.30B | 6.07B | 5.88B |
| Cost of Revenue | 1.47B | 1.44B | 1.40B | 1.33B | 1.28B |
| Gross Profit | 5.21B | 5.07B | 4.91B | 4.73B | 4.60B |
| SG&A Expenses | 2.25B | 2.20B | 2.14B | 2.08B | 1.97B |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -52.80M | -52.00M | -62.30M | -67.20M | -75.60M |
| Total Operating Expenses | 4.75B | 4.68B | 4.56B | 4.43B | 4.26B |
| Operating Income | 1.92B | 1.83B | 1.74B | 1.64B | 1.62B |
| Income Before Tax | 1.43B | 1.42B | 1.30B | 1.27B | 1.57B |
| Income Tax Expenses | 444.70M | 439.00M | 224.90M | 216.90M | 235.80M |
| Earnings from Continuing Operations | 987.70 | 978.60 | 1.07K | 1.06K | 1.34K |
| Earnings from Discontinued Operations | 27.00M | 25.00M | 20.60M | 13.40M | 25.70M |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 6.60M | 1.30M | 2.50M | 4.10M | 5.40M |
| Net Income | 1.02B | 1.00B | 1.10B | 1.07B | 1.37B |
| EBIT | 1.92B | 1.83B | 1.74B | 1.64B | 1.62B |
| EBITDA | 2.09B | 2.00B | 1.90B | 1.79B | 1.78B |
| EPS Basic | 1.77 | 1.73 | 1.88 | 1.83 | 2.33 |
| Normalized Basic EPS | 2.32 | 2.18 | 2.11 | 1.92 | 1.82 |
| EPS Diluted | 1.76 | 1.73 | 1.87 | 1.82 | 2.32 |
| Normalized Diluted EPS | 2.32 | 2.18 | 2.10 | 1.92 | 1.81 |
| Average Basic Shares Outstanding | 2.31B | 2.32B | 2.33B | 2.34B | 2.35B |
| Average Diluted Shares Outstanding | 2.32B | 2.33B | 2.34B | 2.34B | 2.35B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |